NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection

TerminatedPhase 2

Sponsor: HonorHealth Research Institute

Conditions: Covid19

Interventions: Atovaquone/Azithromycin

Countries: United States

This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.

Eligibility overview

Sex: ALL

Age: 18 Years to 95 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Male and Female patients age 18 years or older
* COVID-19 confirmed positive test results
* High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score
* Hematology criteria: ANC \>500 cells/mcl, HGB \>9 g/dl, Platelet count \>75,000/mcl
* Metabolic criteria: Serum creatinine \<2.0 mg/dl or calculated creatinine clearance (using Cockcroft-Gault) \>30 ml/min, AST/ALT \<5x ULN AND Total Bilirubin WNL (for patients with Gilbert's disease, direct bilirubin \<ULN)

Exclusion Criteria:

* COVID-19 negative test result
* Inability to adhere to study protocol requirements
* Inability to provide informed consent
* Other acute or chronic medical or psychiatric condition that in the judgment of the investigator would make the participant inappropriate to take part in the study
* Pregnant and breastfeeding individuals
* QTc interval greater than 470 msecs at baseline
* History of hypersensitivity to atovaquone and/or azithromycin.
* History of known intolerance to atovaquone and/or azithromycin

Locations (1)

Scottsdale, Arizona, United States